Sylvie Castaigne

Le Chesnay, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 38 publications

Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group.

Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy: A Prospective Observational Study From the Acute Leukaemia French Association (ALFA) Group.

Journal: Clinical lymphoma, myeloma & leukemia

Published: September 20, 2021

Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML.

Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML.

Journal: Blood advances

Published: January 21, 2021

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment.

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment.

Journal: International journal of molecular sciences

Published: July 20, 2020

Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia.

Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia.

Journal: Bone marrow transplantation

Published: June 30, 2020

A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis.

A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis.

Journal: Leukemia

Published: November 18, 2019

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia.

Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia.

Journal: Blood

Published: September 24, 2019

Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).

Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).

Journal: Haematologica

Published: May 26, 2018

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial.

Journal: Haematologica

Published: January 17, 2018

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.

Journal: Haematologica

Published: October 29, 2017

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Journal: British journal of haematology

Published: July 06, 2017

Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.

Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 22, 2017

The Plasmair Decontamination System Is Protective Against Invasive Aspergillosis in Neutropenic Patients.

The Plasmair Decontamination System Is Protective Against Invasive Aspergillosis in Neutropenic Patients.

Journal: Infection control and hospital epidemiology

Published: June 25, 2016

Showing 1-12 of 38

Last Updated: 09/26/2026